Status:
TERMINATED
Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Gastrointestinal Neoplasms
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to define the recommended dose of BMS-582664 that could be safely combined with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) or 5-fluorouracil, leucovorin, and oxa...
Eligibility Criteria
Inclusion
- Good performance status
- Advanced colorectal, pancreatic, esophageal or gastric cancer
- Tissue for analyses
- Adequate bone marrow, hepatic, renal function
- 4-6 weeks since prior therapy
- Adequate protection for women of child bearing potential (WOCBP)
Exclusion
- Brain metastasis
- Thromboembolic disease
- Cardiovascular disease
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00300027
Start Date
April 1 2006
Last Update
March 2 2010
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Little Rock, Arkansas, United States
2
Local Institution
Los Angeles, California, United States
3
Local Institution
Washington D.C., District of Columbia, United States
4
Local Institution
Iowa City, Iowa, United States